임상 한눈에 보기

• 1건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• 모집 중 1건 · 완료/종료 11건
• Phase: PHASE1 · PHASE2 · PHASE1, PHASE2
• Status: COMPLETED · ACTIVE_NOT_RECRUITING · TERMINATED
• 주요 endpoint: Safety: Number of Participants With Grade 3 or Grade 4 Adverse Events (AEs) and Laboratory Abnormalities Defined as Dose Limiting Toxicities (DLT) (Phase 1a) · Recommended Dose (RD) of Cabiralizumab in Combination With Nivolumab (Phase 1a) · Safety: Number of Participants With Adverse Events and Serious Adverse Events (Phase 1a and 1b) · Safety: Number of Participants With Treatment Discontinuations · Modifications
• 등록 대상자(표본 합산): 약 766명
• 선택한 코호트 보고값: ORR 20%
• 핵심: A phase II clinical trial is utilized to examine whether BMS-986253 (25 subjects) or Cabiralizumab (25 subjects) when co…

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.